Lafora Disease via the EPM2A Gene
Summary and Pricing 
Test Method
Sequencing and CNV Detection via NextGen Sequencing using PG-Select Capture Probes| Test Code | Test Copy Genes | Test CPT Code | Gene CPT Codes Copy CPT Code | Base Price | |
|---|---|---|---|---|---|
| 10025 | EPM2A | 81404 | 81404,81479 | $990 | Order Options and Pricing |
Pricing Comments
Testing run on PG-select capture probes includes CNV analysis for the gene(s) on the panel but does not permit the optional add on of exome-wide CNV analysis. Any of the NGS platforms allow reflex to other clinically relevant genes, up to whole exome or whole genome sequencing depending upon the base platform selected for the initial test.
An additional 25% charge will be applied to STAT orders. STAT orders are prioritized throughout the testing process.
This test is also offered via a custom panel (click here) on our exome or genome backbone which permits the optional add on of exome-wide CNV or genome-wide SV analysis.
Turnaround Time
3 weeks on average for standard orders or 2 weeks on average for STAT orders.
Please note: Once the testing process begins, an Estimated Report Date (ERD) range will be displayed in the portal. This is the most accurate prediction of when your report will be complete and may differ from the average TAT published on our website. About 85% of our tests will be reported within or before the ERD range. We will notify you of significant delays or holds which will impact the ERD. Learn more about turnaround times here.
Targeted Testing
For ordering sequencing of targeted known variants, go to our Targeted Variants page.
Clinical Features and Genetics
Clinical Features
Lafora disease (LD) is a form of progressive myoclonic epilepsy. During adolescence, LD patients present with myoclonic seizures, headaches, dysarthria, ataxia and hallucinations (Turnbull et al. 2012). Seizures, though at first controlled by anticonvulsants, soon become drug resistant and increase in frequency and severity. Rapid neurodegeneration occurs within 10 years of seizure onset resulting in dementia (Gomez-Abad et al. 2005). Patients are eventually reduced to a vegetative state due to severe myoclonus. LD can be distinguished from other progressive myoclonic epilepsies by the presence of intracellular Lafora bodies, insoluble glycogen aggregates, in neurons and other cells. Lafora bodies can be detected via axillary skin biopsy.
Genetics
Lafora disease is inherited in an autosomal recessive manner and is caused by loss-of-function mutations in the EPM2A or NHLRC1 genes. Mutations in either NHLRC1 or EPM2A result in similar LD phenotypes, with EPM2A mutations resulting in a faster disease progression (Criado et al. 2011; Franceschetti et al. 2006). Missense, nonsense and frameshift mutations in EPM2A have been reported (Singh and Ganesh 2009). Large deletions in the EPM2A gene have also been identified in LD patients (Gomez-Abad et al. 2007; Gómez-Garre et al. 2000). Under normal cellular conditions, glycogen assembles into soluble, spherical polyglucosan structures. In LD patients, polyglucosan structure is disrupted resulting in the formation of insoluble aggregates, known as Lafora bodies. Whether Lafora bodies are the cause of LD or a symptom is unclear, though the number of Lafora bodies in neurons correlates with increased neurodegeneration (Criado et al. 2011). EPM2A encodes the phosphatase, laforin. NHLRC1 encodes malin, a ubiquitin ligase. Laforin and malin localize to the endoplasmic reticulum (ER) where they physically interact. Laforin and malin normally prevent the accumulation of Lafora bodies by regulating enzymes involved in glycogen metabolism and by promoting autophagy and the degradation of Laflora bodies (Liu et al. 2013). Studies in mouse models demonstrate that loss of either laforin or malin results in an accumulation of Lafora bodies in neurons and subsequent neurodegeneration (Turnbull et al. 2011).
Clinical Sensitivity - Sequencing with CNV PG-Select
Pathogenic variants in EPM2A have been reported in 22-68% of patients diagnosed with Lafora disease (Franceschetti et al. 2006; Gómez-Garre et al. 2000).
Testing Strategy
This test provides full coverage of all coding exons of the EPM2A gene, plus ~10 bases of flanking noncoding DNA. We define full coverage as >20X NGS reads or Sanger sequencing.
Indications for Test
Candidates for EPM2A testing include patients with Lafora bodies or other symptoms consistent with a diagnosis of Lafora disease. This test may also be considered for the reproductive partners of individuals who carry pathogenic variants in EPM2A.
Candidates for EPM2A testing include patients with Lafora bodies or other symptoms consistent with a diagnosis of Lafora disease. This test may also be considered for the reproductive partners of individuals who carry pathogenic variants in EPM2A.
Gene
| Official Gene Symbol | OMIM ID |
|---|---|
| EPM2A | 607566 |
| Inheritance | Abbreviation |
|---|---|
| Autosomal Dominant | AD |
| Autosomal Recessive | AR |
| X-Linked | XL |
| Mitochondrial | MT |
Disease
| Name | Inheritance | OMIM ID |
|---|---|---|
| Lafora Disease | AR | 254780 |
Related Test
| Name |
|---|
| Lafora Disease via the NHLRC1 Gene |
Citations
- Criado O, Aguado C, Gayarre J, Duran-Trio L, Garcia-Cabrero AM, Vernia S, San Millan B, Heredia M, Roma-Mateo C, Mouron S, Juana-Lopez L, Dominguez M, et al. 2011. Lafora bodies and neurological defects in malin-deficient mice correlate with impaired autophagy. Human Molecular Genetics 21: 1521–1533. PubMed ID: 22186026
- Franceschetti S, Gambardella A, Canafoglia L, Striano P, Lohi H, Gennaro E, Ianzano L, Veggiotti P, Sofia V, Biondi R. 2006. Clinical and genetic findings in 26 Italian patients with Lafora disease. Epilepsia 47: 640–643. PubMed ID: 16529633
- Gomez-Abad C, Afawi Z, Korczyn AD, Misk A, Shalev SA, Spiegel R, Lerman-Sagie T, Lev D, Kron KL, Gómez-Garre P, Serratosa JM, Berkovic SF. 2007. Founder Effect with Variable Age at Onset in Arab Families with Lafora Disease and EPM2A Mutation. Epilepsia 48: 1011–1014. PubMed ID: 17509003
- Gomez-Abad, C., et al. (2005). "Lafora disease due to EPM2B mutations: a clinical and genetic study." Neurology 64(6):982-986. PubMed ID:15781812 PubMed ID: 15781812
- Gómez-Garre P, Sanz Y, Córdoba SR de, Serratosa JM. 2000. Mutational spectrum of the EPM2A gene in progressive myoclonus epilepsy of Lafora: high degree of allelic heterogeneity and prevalence of deletions. European Journal of Human Genetics 8:946-954. PubMed ID: 11175283
- Liu Y, Zeng L, Ma K, Baba O, Zheng P, Liu Y, Wang Y. 2013. Laforin–Malin Complex Degrades Polyglucosan Bodies in Concert with Glycogen Debranching Enzyme and Brain Isoform Glycogen Phosphorylase. Molecular Neurobiology. PubMed ID: 24068615
- Singh S, Ganesh S. 2009. Lafora progressive myoclonus epilepsy: A meta-analysis of reported mutations in the first decade following the discovery of the EPM2A and NHLRC1 genes. Human Mutation 30: 715–723. PubMed ID: 19267391
- Turnbull J, DePaoli-Roach AA, Zhao X, Cortez MA, Pencea N, Tiberia E, Piliguian M, Roach PJ, Wang P, Ackerley CA, Minassian BA. 2011. PTG Depletion Removes Lafora Bodies and Rescues the Fatal Epilepsy of Lafora Disease. PLoS Genetics 7: e1002037. PubMed ID: 21552327
- Turnbull J, Girard J-M, Lohi H, Chan EM, Wang P, Tiberia E, Omer S, Ahmed M, Bennett C, Chakrabarty A, Tyagi A, Liu Y, et al. 2012. Early-onset Lafora body disease. Brain 135: 2684–2698. PubMed ID: 22961547
Ordering/Specimens
Ordering Options
We offer several options when ordering sequencing tests. For more information on these options, see our Ordering Instructions page. To view available options, click on the Order Options button within the test description.
myPrevent - Online Ordering
- The test can be added to your online orders in the Summary and Pricing section.
- Once the test has been added log in to myPrevent to fill out an online requisition form.
- PGnome sequencing panels can be ordered via the myPrevent portal only at this time.
Requisition Form
- A completed requisition form must accompany all specimens.
- Billing information along with specimen and shipping instructions are within the requisition form.
- All testing must be ordered by a qualified healthcare provider.
For Requisition Forms, visit our Forms page
If ordering a Duo or Trio test, the proband and all comparator samples are required to initiate testing. If we do not receive all required samples for the test ordered within 21 days, we will convert the order to the most effective testing strategy with the samples available. Prior authorization and/or billing in place may be impacted by a change in test code.
Specimen Types
Specimen Requirements and Shipping Details
Loading...
×
ORDER OPTIONS
View Ordering Instructions1) Select Test Type
2) Select Additional Test Options
No Additional Test Options are available for this test.